Study Summary
This trial is testing a drug that could treat human cancers by blocking a certain protein. It will evaluate safety, effectiveness, and other factors.
- Solid Tumors
- Triple Negative Breast Cancer
- Hormone Receptor Positive Tumor
- Advanced Cancer
- Metastatic Breast Cancer
- Breast Cancer
- CCNE1 Amplification
- Metastatic Cancer
- Ovarian Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
5 Primary · 11 Secondary · Reporting Duration: Up to 36 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
3 Treatment Groups
Part B: Ovarian Dose Expansion
1 of 3
Part A: Dose Escalation
1 of 3
Part C: ER+/HER2- BC Dose Expansion
1 of 3
Experimental Treatment
81 Total Participants · 3 Treatment Groups
Primary Treatment: Part B: Ovarian Dose Expansion · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is there an opportunity to join this clinical research at the current moment?
"Affirmative. According to the clinicaltrials.gov portal, this medical trial is presently enrolling 81 individuals from a single site. The initial post for this study was created on March 28th 2023 and it has since been updated with new information that same day." - Anonymous Online Contributor
Could you tell me the aggregate number of individuals involved in this trial?
"Indeed, data hosted on clinicaltrials.gov verifies that this medical research is currently enlisting volunteers. The study was initially listed in the public domain on March 28th 2023 and has since been updated once more to reflect its current recruitment status. As of now, 81 participants will be accepted at a single site." - Anonymous Online Contributor